Lite Strategy (LITS) Change in Receivables (2021)
Lite Strategy (LITS) posted quarterly Change in Receivables of -$10.0 million for Q4 2021, down 200.0% quarter-over-quarter from $10.0 million in Q3 2021.
Lite Strategy (LITS) Change in Receivables (2021) Analysis & Trends
Lite Strategy's Change in Receivables history runs 1 years deep, the most recent figure standing at -$10.0 million for Q4 2021.
- In Q4 2021, Change in Receivables changed N/A year-over-year to -$10.0 million; the TTM figure through Mar 2022 stood at $25.1 million (changed N/A YoY), while the FY2021 annual figure was $4.7 million, up 101.28% from the prior year.
- Change in Receivables for Q4 2021 stood at -$10.0 million, down from $10.0 million in the prior quarter.
- The five-year high for Change in Receivables was $25.1 million in Q2 2021, with the low at -$10.0 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -10.00 Mn |
| Dec 31, 2021 | -10.00 Mn |
| Sep 30, 2021 | 10.00 Mn |
| Sep 30, 2021 | 10.00 Mn |
| Jun 30, 2021 | 25.14 Mn |
| Jun 30, 2021 | 25.14 Mn |